Article
Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Arthritis and rheumatism - 1 Jan 2009
Akhmetshina Alfiya, Venalis Paulius, Dees Clara, Busch Nicole, Zwerina Jochen, Schett Georg, Distler Oliver, Distler Jörg H W
Abstract excerpt
OBJECTIVE: Imatinib is a small-molecule tyrosine kinase inhibitor capable of selective, dual inhibition of the transforming growth factor beta and platelet-derived growth factor (PDGF) pathways. Imatinib has previously been shown to prevent the development of inflammation-driven experimental fibrosis when treatment was initiated before administration of the profibrotic stimulus. The aim of this study was to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
